Urteste SA (URT) - Total Liabilities
Based on the latest financial reports, Urteste SA (URT) has total liabilities worth zł16.75 Million PLN (≈ $4.61 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Urteste SA annual equity growth to track the company's year-over-year net asset growth rate.
Urteste SA - Total Liabilities Trend (2019–2025)
This chart illustrates how Urteste SA's total liabilities have evolved over time, based on quarterly financial data. See URT free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Urteste SA Competitors by Total Liabilities
The table below lists competitors of Urteste SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dare Bioscience Inc
NASDAQ:DARE
|
USA | $29.63 Million |
|
Volitionrx Ltd
NYSE MKT:VNRX
|
USA | $42.49 Million |
|
Artmarket.com SA
PA:PRC
|
France | €5.80 Million |
|
GLORY HEALTH IND. HD-001
F:84R
|
Germany | €43.59 Billion |
|
UMS Holdings Bhd
KLSE:7137
|
Malaysia | RM8.35 Million |
|
Smart Concrete Public Company Limited
BK:SMART
|
Thailand | ฿95.74 Million |
|
M VEST WATER NK-00227652
F:7YA
|
Germany | €9.97 Million |
|
Salee Colour Public Company Limited
BK:COLOR
|
Thailand | ฿518.52 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Urteste SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Urteste SA market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Urteste SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Urteste SA (2019–2025)
The table below shows the annual total liabilities of Urteste SA from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | zł20.21 Million ≈ $5.56 Million |
+266.97% |
| 2024-12-31 | zł5.51 Million ≈ $1.52 Million |
+196.87% |
| 2023-12-31 | zł1.85 Million ≈ $510.52K |
+72.88% |
| 2022-12-31 | zł1.07 Million ≈ $295.31K |
+325.72% |
| 2021-12-31 | zł252.04K ≈ $69.37K |
+1284.40% |
| 2020-12-31 | zł18.21K ≈ $5.01K |
-58.64% |
| 2019-12-31 | zł44.02K ≈ $12.12K |
-- |
About Urteste SA
Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.